ARS Pharmaceuticals (SPRY) Competitors $17.18 -0.50 (-2.83%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.32 +0.14 (+0.79%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY vs. GRFS, TGTX, NUVL, CRSP, RYTM, TLX, AXSM, LNTH, PCVX, and CYTKShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Lantheus (LNTH), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Its Competitors Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Telix Pharmaceuticals Axsome Therapeutics Lantheus Vaxcyte Cytokinetics ARS Pharmaceuticals (NASDAQ:SPRY) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do insiders and institutionals have more ownership in SPRY or GRFS? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer SPRY or GRFS? In the previous week, Grifols had 3 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 8 mentions for Grifols and 5 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.61 beat Grifols' score of 0.52 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SPRY or GRFS? ARS Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Do analysts prefer SPRY or GRFS? ARS Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 80.44%. Grifols has a consensus target price of $10.30, suggesting a potential downside of 4.45%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SPRY or GRFS more profitable? Grifols has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. Grifols' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-16.11% -6.94% -5.60% Grifols N/A N/A N/A Which has better earnings & valuation, SPRY or GRFS? Grifols has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$97.12M17.37$8M-$0.16-107.38Grifols$7.81B0.95$169.80M$1.179.21 SummaryARS Pharmaceuticals and Grifols tied by winning 8 of the 16 factors compared between the two stocks. Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$2.46B$5.48B$9.52BDividend YieldN/A1.81%4.73%4.08%P/E Ratio-107.378.9728.6723.80Price / Sales17.37437.63373.5466.64Price / Cash2,087.79157.7635.4557.96Price / Book6.514.838.275.55Net Income$8M$31.62M$3.24B$259.03M7 Day Performance-3.86%-5.28%-3.69%-4.59%1 Month Performance2.57%4.38%4.33%4.46%1 Year Performance73.54%-2.49%25.95%18.03% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals3.0361 of 5 stars$17.18-2.8%$31.00+80.4%+63.8%$1.74B$97.12M-107.3790Positive NewsUpcoming EarningsGRFSGrifols3.1017 of 5 stars$10.00+0.6%$10.30+3.0%+41.1%$6.88B$7.81B8.5523,822Dividend AnnouncementTGTXTG Therapeutics4.0843 of 5 stars$37.42-1.3%$43.80+17.0%+85.0%$5.94B$329M155.92290Positive NewsUpcoming EarningsNUVLNuvalent3.2027 of 5 stars$82.46-1.1%$119.60+45.0%+2.0%$5.92BN/A-18.7840Positive NewsCRSPCRISPR Therapeutics2.7909 of 5 stars$65.33+0.3%$71.75+9.8%+2.3%$5.64B$37.31M-14.45460Upcoming EarningsAnalyst RevisionGap UpHigh Trading VolumeRYTMRhythm Pharmaceuticals3.4446 of 5 stars$88.63-0.6%$91.93+3.7%+88.5%$5.64B$130.13M-31.54140Upcoming EarningsInsider TradeTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.58B$516.72M0.00N/AGap DownHigh Trading VolumeAXSMAxsome Therapeutics4.8236 of 5 stars$109.68-1.8%$172.33+57.1%+19.8%$5.40B$385.69M-19.01380Positive NewsUpcoming EarningsLNTHLantheus4.6154 of 5 stars$71.56+2.0%$131.20+83.3%-28.4%$4.95B$1.53B20.33700News CoverageUpcoming EarningsAnalyst RevisionPCVXVaxcyte2.2402 of 5 stars$35.64-1.6%$136.50+283.0%-58.0%$4.60BN/A-8.93160News CoveragePositive NewsUpcoming EarningsCYTKCytokinetics4.0154 of 5 stars$36.96-0.7%$70.92+91.9%-36.6%$4.41B$18.47M-6.99250News CoverageUpcoming EarningsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies GRFS Competitors TGTX Competitors NUVL Competitors CRSP Competitors RYTM Competitors TLX Competitors AXSM Competitors LNTH Competitors PCVX Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRY Stock Alerts